Durham, N.C.
You’ve probably never heard of biallelic RPE65 mutation—and count yourself lucky. It’s a genetic defect that causes a form of retinal dystrophy. People born with it gradually lose their vision, often while still children, until they go totally blind. But they are now fortunate: In December the Food and Drug Administration approved a new gene therapy called Luxturna that corrects the mutation and reverses the course of the disease. Patients don’t get normal vision back but can read facial expressions and see stars... 